This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements involve risks and uncertainties, including activities,
events or developments that the company expects, believes or
anticipates will or may occur in the future. A number of factors could
cause actual results to differ from those indicated in the
forward-looking statements, including the Company's ability to
continue to successfully develop new formulations, initiate and
complete successful human clinical trials, obtain regulatory approval,
to market and to provide its products and services and maintain their
effectiveness, the continuation of arrangements with the Company's
product development partners and customers, competition, government
regulation, and general economic conditions. Such statements are
subject to a number of assumptions, risks and uncertainties which are
described in detail in our registration statements, reports and other
filings with the Securities and Exchange Commission. Such filings are
available on our website or at www.sec.gov. Readers are cautioned that
such statements are not guarantees of future performance and that
actual results or developments may differ materially from those set
forth in the forward-looking statements. The Company undertakes no
obligation to publicly update or revise forward-looking statements to
reflect subsequent events or circumstances.
-=-=-
C O P Y R I G H T * R E M I N D E R
This article is Copyright 2004 by Business Wire.
All articles in the clari.* news hierarchy are Copyrighted and licensed
to ClariNet Communications Corp. for distribution. Except for articles
in the biz.clarinet newsgroups, only paid subscribers may access
these articles. Any unauthorized access, reproduction or transmission
is strictly prohibited.
We offer a reward to the person who first provides us with
information that helps stop those who distribute or receive our news
feeds without authorization. Please send reports to rew...@clari.net.
[Use in...@clari.net for sales or other inquiries.]
Details on the use of ClariNet material and other info can be found in
the user documentation section of <<our web page>> <http://www.clari.net>.